| Jonathan Zoghby, MD | |
|
2606 S. Lamar, Oxford, MS 38655-5302 | |
| (662) 234-6551 | |
| (662) 234-0468 |
| Full Name | Jonathan Zoghby |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 15 Years |
| Location | 2606 S. Lamar, Oxford, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962631150 | NPI | - | NPPES |
| 06621825 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 23027 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rayner Eye Clinic, Llc | 9537136577 | 10 |
News Archive
Researchers at Duke University School of Medicine and Brigham and Women's Hospital, Harvard Medical School have identified a mechanism that explains why some mutations can be disease-causing in one genome but benign in another.
Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced a net loss of $4.1 million or $0.58 per diluted share on net sales from continuing operations of $73.9 million for the fiscal year ended June 30, 2009.
Policing is dangerous work, and the danger lurks not on the streets alone. The pressures of law enforcement put officers at risk for high blood pressure, insomnia, increased levels of destructive stress hormones, heart problems, post-traumatic stress disorder (PTSD) and suicide, University at Buffalo researchers have found through a decade of studies of police officers.
Every cell in the body, whether skin or muscle or brain, starts out as a generic cell that acquires its unique characteristics after undergoing a process of specialization. Nowhere is this process more dramatic than it is in red blood cells.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version. The court found these patents to be invalid for lack of written description.
› Verified 6 days ago
| Entity Name | Rayner Eye Clinic, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326148578 PECOS PAC ID: 9537136577 Enrollment ID: O20040910000538 |
News Archive
Researchers at Duke University School of Medicine and Brigham and Women's Hospital, Harvard Medical School have identified a mechanism that explains why some mutations can be disease-causing in one genome but benign in another.
Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced a net loss of $4.1 million or $0.58 per diluted share on net sales from continuing operations of $73.9 million for the fiscal year ended June 30, 2009.
Policing is dangerous work, and the danger lurks not on the streets alone. The pressures of law enforcement put officers at risk for high blood pressure, insomnia, increased levels of destructive stress hormones, heart problems, post-traumatic stress disorder (PTSD) and suicide, University at Buffalo researchers have found through a decade of studies of police officers.
Every cell in the body, whether skin or muscle or brain, starts out as a generic cell that acquires its unique characteristics after undergoing a process of specialization. Nowhere is this process more dramatic than it is in red blood cells.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version. The court found these patents to be invalid for lack of written description.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Zoghby, MD 1308 Belk Blvd, Oxford, MS 38655 Ph: (662) 234-6551 | Jonathan Zoghby, MD 2606 S. Lamar, Oxford, MS 38655-5302 Ph: (662) 234-6551 |
News Archive
Researchers at Duke University School of Medicine and Brigham and Women's Hospital, Harvard Medical School have identified a mechanism that explains why some mutations can be disease-causing in one genome but benign in another.
Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced a net loss of $4.1 million or $0.58 per diluted share on net sales from continuing operations of $73.9 million for the fiscal year ended June 30, 2009.
Policing is dangerous work, and the danger lurks not on the streets alone. The pressures of law enforcement put officers at risk for high blood pressure, insomnia, increased levels of destructive stress hormones, heart problems, post-traumatic stress disorder (PTSD) and suicide, University at Buffalo researchers have found through a decade of studies of police officers.
Every cell in the body, whether skin or muscle or brain, starts out as a generic cell that acquires its unique characteristics after undergoing a process of specialization. Nowhere is this process more dramatic than it is in red blood cells.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version. The court found these patents to be invalid for lack of written description.
› Verified 6 days ago
Randy K Richardson, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2606 S. Lamar, Oxford, MS 38655 Phone: 662-234-6551 | |
Thomas M Tann Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2606 S. Lamar, Oxford, MS 38655 Phone: 662-234-6551 | |
Dr. Emily Taylor Graves, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2606 S. Lamar, Oxford, MS 38655 Phone: 662-234-6551 | |
Blake A Booth, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1308 Belk Blvd, Oxford, MS 38655 Phone: 662-234-6551 Fax: 662-234-0468 | |
Dr. William Sumners Mayo, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1628 Highway 30 East, Oxford, MS 38655 Phone: 662-234-3937 Fax: 662-234-3898 | |
Dr. James W Rayner, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1308 Belk Blvd, Oxford, MS 38655 Phone: 662-234-6551 | |
Mr. James Byron Shipp, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1628 Highway 30 East, Oxford, MS 38655 Phone: 662-234-3937 Fax: 662-234-3898 |